Atlas Trials

Iovance Biotherapeutics, Inc.

16 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Iovance Biotherapeutics, Inc.

RecordFirmDate
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma (NCT07741877)Iovance Biotherapeutics, Inc.2026-09-01
A Study of IOV-5001 in Adults With Advanced Solid Tumors (NCT07743723)Iovance Biotherapeutics, Inc.2026-08-01
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (NCT07288203)Iovance Biotherapeutics, Inc.2025-11-28
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel (NCT06940739)Iovance Biotherapeutics, Inc.2025-03-11
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. (NCT06481592)Iovance Biotherapeutics, Inc.2024-10-29
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants (NCT06566092)Iovance Biotherapeutics, Inc.2024-03-28
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. (NCT05727904)Iovance Biotherapeutics, Inc.2023-03-30
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (NCT05361174)Iovance Biotherapeutics, Inc.2022-07-20
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (NCT04614103)Iovance Biotherapeutics, Inc.2021-05-07
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (NCT04155710)Iovance Biotherapeutics, Inc.2020-02-19
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (NCT03645928)Iovance Biotherapeutics, Inc.2019-05-07
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer (NCT03419559)Iovance Biotherapeutics, Inc.2018-02-28
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma (NCT03108495)Iovance Biotherapeutics, Inc.2017-06-22
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck (NCT03083873)Iovance Biotherapeutics, Inc.2017-01-09
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (NCT02360579)Iovance Biotherapeutics, Inc.2015-09-24
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release (NCT05398640)Iovance Biotherapeutics, Inc.

Track Iovance Biotherapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.